印度的CRDMO部门价值为3B美元,其增长迅速,吸引了来自中国的全球投资者。 India's CRDMO sector, valued at $3B, sees rapid growth, attracting global investors amidst a shift from China.

印度的CRDMO部门价值30亿美元,在五年内增长14%的CAGR,吸引全球投资者,市场上限为400至500亿美元。 India's CRDMO sector, worth $3 billion, has grown at a 14% CAGR over five years and attracts global investors with a $40-50 billion market cap. 最近一份报告预测,在药物管道、大药厂的“中国+1”战略以及体重损失和2型糖尿病药物的增长驱动下,到30财政年度,CAGR将达到18%。 A recent report predicts an 18% CAGR to FY30, driven by drug pipelines, Big Pharma's "China+1" strategy, and growth in weight-loss and Type 2 diabetes drugs. 从中国公司向印度公司的转变每年可能带来7亿到14亿美元。 The shift from Chinese to Indian firms could bring $700 million to $1.4 billion annually.